Tyra Biosciences, Inc.
HealthcareNASDAQ:TYRA · NASDAQ Global Select
+$1.42 today
Vol 1.01M · Avg 0.96M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.3%
avg 2.6%
ROIC
-50.1%
avg -20.7%
ROA
-42.4%
avg -136.1%
Analysis
ROA is currently the strongest return metric at -42.4% versus its period average of -136.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Todd Harris | Co-Founder, CEO, President & Director | $998,960.00 | — | 47 | $1.44M | 2.42% |
Douglas Warner | Chief Medical Officer | $764,683.00 | — | 54 | $85,000.00 | 0.14% |
Alan Fuhrman | Chief Financial Officer | $763,093.00 | — | 69 | $67,000.00 | 0.11% |
Daniel Bensen | Co-Founder & Chief Discovery Officer | $737,643.00 | — | 51 | $152,853.00 | 0.26% |
Ali D. Fawaz | General Counsel & Secretary | $629,230.00 | — | — | $361,586.00 | 0.61% |
Bhavesh Ashar | Chief Operating Officer | $551,017.00 | — | 57 | $50,295.00 | 0.08% |
Ronald V. Swanson | Chief Scientific Officer | $536,188.00 | — | 63 | $273,254.00 | 0.46% |
Julia Rueb | VP of Finance & Principal Accounting Officer | — | — | 40 | $43,354.00 | 0.07% |
Erik Goluboff | Senior Vice President of Clinical Development | — | — | — | — | — |
Sarah Honig | Senior Vice President of Corporate Development & Strategy | — | — | — | — | — |
Robert L. Hudkins | Chief Technology Officer | — | — | 71 | $13,160.00 | 0.02% |
Liz Pagano | Chief Human Resources Officer | — | — | — | — | — |
Ralph William Charlton | Senior Vice President of Clinical Development | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$1.35M
Sells
18
$10.91M
Net Sentiment
$9.56M
Net selling
Most Active
Bensen Daniel
11 transactions
1–10 of 20
Analysis
Insiders reported 2 buys worth $1.35M and 18 sells worth $10.91M over the last 12 months. That adds up to net selling of $9.56M. Bensen Daniel was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages TYRA?
Tyra Biosciences, Inc. (TYRA) lists 13 active executives. The top listed executive is Bhavesh Ashar, Chief Operating Officer.
Are TYRA insiders buying or selling?
Recent insider activity shows net buying of $124.67M.
Explore More
Continue the stock analysis
Jump to another research area for this company.